Literature DB >> 18521272

Expression of smooth muscle calponin in synovial sarcoma.

H Ono1, H Yoshikawa, T Ueda, H Yamamura, I Kudawara, M Manou, S Ishiguro, H Funai, Y Koyanagi, N Araki, N Hashimoto, H Sonobe, M Tatsuta, K Takahashi.   

Abstract

Purpose. Histogenesis of synovial sarcoma remains controversial and reliable molecular markers for diagnosis are necessary. Expression of basic calponin, a smooth muscle differentiation-specific actin-binding protein, was studied in synovial sarcoma.Subjects and Methods. The basic calponin gene and the gene product were analyzed by reverse transcription PCR analysis (RT-PCR) and immunohistochemistry in 14 synovial sarcomas and a human synovial sarcoma cell line (HS-SY-II).Results and Discussion. Immunoreactivity for basic calponin was detected in the cytoplasm of 6 synovial sarcomas (43% positive). In the basic calponin-positive tumors and the HS-SY-II cells, expression for smooth muscle-specific genes, including basic calponin and SM22alpha , was detected by RT-PCR, suggesting a lineage relationship between synovial sarcoma cells and smooth muscle-like mesenchymal cells.Conclusions. A subset of synovial sarcomas expressing the basic calponin gene and the gene product were identified. The basic calponin may have potential utility as a novel molecular marker identifying certain synovial sarcomas.

Entities:  

Year:  1999        PMID: 18521272      PMCID: PMC2395415          DOI: 10.1080/13577149977730

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  32 in total

1.  Smooth muscle specific expression of calponin.

Authors:  M Gimona; M Herzog; J Vandekerckhove; J V Small
Journal:  FEBS Lett       Date:  1990-11-12       Impact factor: 4.124

2.  Molecular cloning and sequence analysis of smooth muscle calponin.

Authors:  K Takahashi; B Nadal-Ginard
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

3.  Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential.

Authors:  S Katzav; J L Cleveland; H E Heslop; D Pulido
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

4.  Vascular smooth muscle calponin. A novel troponin T-like protein.

Authors:  K Takahashi; K Hiwada; T Kokubu
Journal:  Hypertension       Date:  1988-06       Impact factor: 10.190

5.  Mechanism of activation of the vav protooncogene.

Authors:  J Coppola; S Bryant; T Koda; D Conway; M Barbacid
Journal:  Cell Growth Differ       Date:  1991-02

6.  The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization.

Authors:  J M Adams; H Houston; J Allen; T Lints; R Harvey
Journal:  Oncogene       Date:  1992-04       Impact factor: 9.867

7.  The potential histogenic relationship of the peripheral nerve to synovioma.

Authors:  H Ichinose; L Powell; H E Hoerner; V J Derbes; J F Byers
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

8.  Calcifying synovial sarcoma.

Authors:  J Varela-Duran; F M Enzinger
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

9.  Synovial sarcoma: a clinical, pathological, and ultrastructural study of 26 cases supporting the recognition of a monophasic variant.

Authors:  R A Krall; M Kostianovsky; A S Patchefsky
Journal:  Am J Surg Pathol       Date:  1981-03       Impact factor: 6.394

10.  Synovial sarcomas. True carcinosarcomas?

Authors:  M Leader; J Patel; M Collins; H Kristin
Journal:  Cancer       Date:  1987-06-15       Impact factor: 6.860

View more
  2 in total

1.  Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.

Authors:  T Ueda; N Araki; M Mano; A Myoui; S Joyama; S Ishiguro; H Yamamura; K Takahashi; I Kudawara; H Yoshikawa
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

Review 2.  Herpes simplex virus oncolytic therapy for pediatric malignancies.

Authors:  Gregory K Friedman; Joseph G Pressey; Alyssa T Reddy; James M Markert; G Yancey Gillespie
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.